P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML. (23rd June 2022) - Byrd, J. C.; Cortes, J. E.; Minden, M. D.; Oellerich, T.; Stein, E. M.; Elder, J.; Kumar, P.; Bray, G.; DiMartino, J.; Stock, W.